Regional Citrate Anticoagulation Versus Systemic Heparin in Continuous Kidney Replacement Therapy: Examining the Role of Evidence in Health Technology Assessment
Carla Rognoni, Robert Pohlmeier, Rosanna Tarricone
Springer Nature ·
2025-04-16
· DOI 10.1007/s12325-025-03186-8
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Carla Rognoni, Robert Pohlmeier, Rosanna Tarricone. Regional Citrate Anticoagulation Versus Systemic Heparin in Continuous Kidney Replacement Therapy: Examining the Role of Evidence in Health Technology Assessment. // Advances in Therapy. – 2025. – DOI: 10.1007/s12325-025-03186-8. – URL: https://doi.org/10.1007/s12325-025-03186-8
Carla Rognoni, Robert Pohlmeier, & Rosanna Tarricone (2025). Regional Citrate Anticoagulation Versus Systemic Heparin in Continuous Kidney Replacement Therapy: Examining the Role of Evidence in Health Technology Assessment. Advances in Therapy. https://doi.org/10.1007/s12325-025-03186-8
Carla Rognoni, et al. “Regional Citrate Anticoagulation Versus Systemic Heparin in Continuous Kidney Replacement Therapy: Examining the Role of Evidence in Health Technology Assessment.” Advances in Therapy, 2025. doi:10.1007/s12325-025-03186-8.
@article{Rognoni2025,
title = {Regional Citrate Anticoagulation Versus Systemic Heparin in Continuous Kidney Replacement Therapy: Examining the Role of Evidence in Health Technology Assessment},
author = {Rognoni, Carla and Pohlmeier, Robert and Tarricone, Rosanna},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03186-8},
url = {https://doi.org/10.1007/s12325-025-03186-8}
}